Loss of hepatic parenchymal cells leads to decreased plasma levels of all plasma coagulation factors except factor VIII and von Willebrand factor.
Thrombocytopenia occurs frequently and is usually a result of splenic sequestration (see Chap. 74), but may also be caused by an autoimmune mechanism, disseminated intravascular coagulation (DIC), folic acid deficiency, and decreased platelet production. In some patients, thrombocytopenia due to thrombopoietin (TPO) deficiency and platelet dysfunction contribute to the hemostatic abnormalities.
Enhanced fibrinolysis is common, and appears to be caused by complex pathogenetic mechanisms, including release and impaired clearance of plasminogen activators.
Dysfibrinogenemia is relatively frequently found in patients with chronic liver disease.
Patients with chronic liver disease may develop DIC.
Patients with chronic liver disease may present with purpura, epistaxis, gingival bleeding, and/or menorrhagia.
Bleeding may follow trauma or surgical procedures, especially in sites with high fibrinolytic activity, such as the urogenital tract or oral mucosa.
Patients with acute viral or toxic hepatitis usually develop abnormal bleeding only if the disease is fulminant.
Bleeding from esophageal varices requires primary attention to the bleeding site as well as efforts to correct the hemostatic abnormalities.
The coagulopathy of liver disease may also predispose the patient to thromboembolic complications.
Table 84–1 summarizes the laboratory abnormalities that can be found in patients with chronic liver disease. These abnormalities may both contribute to bleeding or thrombosis.
Determination of plasma levels of factors V, VII, and VIII may help differentiate liver disease (factor VIII levels normal or increased; factors V and VII decreased), vitamin K deficiency (factor VII decreased; factors V and VIII normal), and DIC (all decreased).
TABLE 84–1ALTERATIONS IN THE HEMOSTATIC SYSTEM IN PATIENTS WITH LIVER DISEASE THAT CONTRIBUTE TO BLEEDING (LEFT) OR COUNTERACT BLEEDING (RIGHT) |Favorite Table|Download (.pdf) TABLE 84–1 ALTERATIONS IN THE HEMOSTATIC SYSTEM IN PATIENTS WITH LIVER DISEASE THAT CONTRIBUTE TO BLEEDING (LEFT) OR COUNTERACT BLEEDING (RIGHT)
|Changes That Impair Hemostasis ||Changes That Promote Hemostasis |
|Thrombocytopenia ||Elevated levels of VWF |
|Platelet function defects ||Decreased levels of ADAMTS-13 |
|Enhanced production of nitric oxide and prostacyclin ||Elevated levels of factor VIII |
|Low levels of factors II, V, VII, IX, X, and XI ||Decreased levels of protein C, protein S, antithrombin, and heparin cofactor II |
|Vitamin K deficiency ||Low levels of plasminogen |
|Dysfibrinogenemia || |
|Low levels of α2-antiplasmin, factor XIII, and TAFI || |
|Elevated t-PA levels || |
Correction of coagulation is only required in case of bleeding or when an invasive procedure has to be performed.
Replacement of all the deficient coagulation factors may be attempted with fresh-frozen plasma, but large volumes ...
Log In to View More
If your institution is currently a subscriber
of the HemOnc Collection please sign in below.
If your institution is not a subscriber
please click here
to learn more.
Want remote access to your institution's subscription?
Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.
If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.
Pop-up div Successfully Displayed
This div only appears when the trigger link is hovered over.
Otherwise it is hidden from view.